Publication:
Safety Monitoring of Medicines and Vaccines: A Situation Analysis

Simple item page
dc.contributor.authorWang, Huihui
dc.contributor.authorMarquez, Patricio V.
dc.contributor.authorBieliaieva, Kseniya
dc.date.accessioned2023-08-15T17:52:21Z
dc.date.available2023-08-15T17:52:21Z
dc.date.issued2023-08-15
dc.description.abstractMedicines, vaccines, medical devices, and blood are commonly used to treat disease. Medicines deserve a special focus because almost any medical visit ends with at least one prescription. So, monitoring the safety and effectiveness of therapeutic treatments and procedures is crucial at both the individual and community levels. In the case of medicines and vaccines, this surveillance activity is known as pharmacovigilance. Various methods are used to monitor the adverse and unwanted effects of medicinal products after they have received authorization for marketing, but reporting adverse reactions is the most widespread. The network of the Program for International Drug Monitoring (PIDM), which is supported by the World Health Organization (WHO), involves more than 170 countries. Its activities were initiated in 1968. The WHO-PIDM is the world’s most comprehensive network involving health professionals, patients, and manufacturers. This situation analysis describes relevant aspects of the PIDM, including achievements and weak points. The analysis is the product of a systematic revision of studies that focus on the WHO-PIDM activities and related findings published in different medical journals and listed in PubMed. Available information was selected and organized according to different topics and summarized and presented in the different sections of the report. As information for some countries and regions is lacking in the available literature, the report is not a comprehensive review of the pharmacovigilance across countries. The report, therefore, shows what is in place and highlight some of the difficulties faced by many countries, particularly low-and-middle income countries. It offers an overview of the (1) common points and failures; (2) the advantages of a national PV system; (3) the difficulties in scaling up and consolidating these systems; and (4) the advantages of regional collaboration. This report is part of a series of companion reports on pharmacovigilance, that provide a detailed overview and discussion on technical aspects and country and regional experiences.en
dc.identifierhttp://documents.worldbank.org/curated/en/099710108102319104/IDU06f690bb30d6ce047840980f08dac22228820
dc.identifier.doi10.1596/40197
dc.identifier.urihttps://openknowledge.worldbank.org/handle/10986/40197
dc.languageEnglish
dc.language.isoen
dc.publisherWorld Bank, Washington, DC
dc.relation.ispartofseriesPharmacovigilance and Essential Public Health Services Series
dc.rightsCC BY-NC 3.0 IGO
dc.rights.holderWorld Bank
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/igo
dc.subjectKOREA-WORLD BANK PARTNERSHIP FACILITY (KWPF)
dc.subjectCHINA-WORLD BANK PARTNERSHIP TRUST FUND (CWPF)
dc.subjectMEDICATION EFFECTIVENESS MONITORING
dc.subjectPHARMACOVIGILANCE
dc.subjectPUBLIC HEALTH SURVEILLANCE
dc.subjectPROGRAM FOR INTERNATIONAL DRUG MONITORING (PIDM)
dc.subjectVACCINE EFFECTIVENESS MONITORING
dc.titleSafety Monitoring of Medicines and Vaccinesen
dc.title.subtitleA Situation Analysisen
dc.typeReport
dspace.entity.typePublication
okr.crossref.titleSafety Monitoring of Medicines and Vaccines: A Situation Analysis
okr.date.disclosure2023-08-10
okr.date.lastmodified2023-08-11T00:00:00Zen
okr.doctypeReport
okr.doctypePublications & Research
okr.docurlhttp://documents.worldbank.org/curated/en/099710108102319104/IDU06f690bb30d6ce047840980f08dac22228820
okr.guid099710108102319104
okr.identifier.docmidIDU-6f690bb3-d6ce-4784-980f-8dac22228820
okr.identifier.doihttp://dx.doi.org/10.1596/40197
okr.identifier.externaldocumentum34133702
okr.identifier.internaldocumentum34133702
okr.identifier.report184487
okr.import.id1487
okr.importedtrueen
okr.language.supporteden
okr.pdfurlhttp://documents.worldbank.org/curated/en/099710108102319104/pdf/IDU06f690bb30d6ce047840980f08dac22228820.pdfen
okr.sectorHealth-HG
okr.themeHealth Systems and Policies,Health Service Delivery,Pandemic Response,Health System Strengthening,Disease Control,Human Development and Gender,Health Systems and Policies,Adolescent Health,Child Health,Health System Strengthening,Health Service Delivery,Health Finance,Reproductive and Maternal Health,Private Sector Delivery in Health,Human Development and Gender
okr.topicHealth, Nutrition and Population::Health Monitoring & Evaluation
okr.topicHealth, Nutrition and Population::Immunizations
okr.topicHealth, Nutrition and Population::Pharmaceuticals & Pharmacoeconomics
okr.topicHealth, Nutrition and Population::Disease Control & Prevention
okr.unitHNP Global (HHNGE)
relation.isAuthorOfPublication601b45de-9e7b-5045-bfef-0689612779d8
relation.isAuthorOfPublication.latestForDiscovery601b45de-9e7b-5045-bfef-0689612779d8
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
IDU06f690bb30d6ce047840980f08dac22228820.pdf
Size:
1.67 MB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
IDU06f690bb30d6ce047840980f08dac22228820.txt
Size:
160.47 KB
Format:
Plain Text
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download
Collections
Other Health Study